Ingrid Cruzado-Park from Beckman Coulter, Inc to Present at GTCbio's 2nd Protein Therapeutics Discovery & Development Conference
Ingrid Cruzado-Park from Beckman Coulter, Inc to Present at GTCbio's 2nd Protein Therapeutics Discovery & Development conference on September 8-9, 2008 in San Diego, CA


/Biotechnology News Articles/ - MONROVIA, CA, June 13, 2008 - Dr. Ingrid D. Cruzado-Park, Senior Development Scientist at Beckman Coulter will speak at GTCbio's 2nd Protein Therapeutics Discovery & Development conference on September 8-9, 2008 in San Diego, CA. Dr. Cruzado-Park will present on cIEF analysis of monoclonal antibodies with high-resolution and reproducibility.

During development and manufacture of therapeutic monoclonal antibodies (MAbs), characterization of protein glycosylation is critical. Glycoforms of purified MAbs are usually separated by differences in isoelectric point (pI). Capillary Isoelectric Focusing (cIEF) is a separation technique that has been successful in generating glycosylation profiles of MAbs. Faster separations can be achieved with cIEF than with IEF-gel electrophoresis. When compared with Imaging IEF systems, cIEF provides higher resolution due to the use of longer capillaries. However, cIEF is an inherently complex technique and understanding it is essential to achieving success. For example, the use of a protein solubilizer is critical in preventing MAbs aggregation and precipitation during focusing. In addition, the pI measurement is more accurate and precise when using synthetic peptides as pI markers rather than using proteins. The use of stabilizers can reduce distortions in the pH gradient and improve resolution. Optimization of the ampholyte volume, focusing time and amount of stabilizers is essential in achieving the resolution required.

Dr. Cruzado-Park's presentation will describe how to achieve maximum resolution and reproducibility in cIEF. In addition, it will provide guidelines for the development of cIEF methods. Other benefits of the presentation will include learning how to characterize therapeutic antibodies by cIEF, finding out the key steps in cIEF method development and realizing that high resolution and reproducibility can indeed be achieved in cIEF.

GTCbio's 2nd Annual Protein Therapeutics Discovery and Development Conference will explore the therapeutic applications of proteins, with a look at discovery and design of therapeutics, overcoming challenges associated with protein based drugs, and new tools and strategies in process development. Finally, attendees will get an update on novel developments in protein therapeutics. The keynote presentation will be given by Dr. Michael Hanley, Vice President of Discovery Research & CSO of Amylin Pharmaceuticals.

For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/conferenceDetails.aspx?id=128.

Further Related Resources:


Press Release Contact Information:

Rania Hafez
GTCbio
Marketing Director
434 W. Foothill Blvd.
Monrovia, CA
USA 91106
Voice: 626-256-6405
Fax: 626-256-6460
Website: Visit Our Website